India's largest Xanthine derivatives maker and a leading small-molecule CDMO/API manufacturer for global pharma clients.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 0 | 0 | 45 | 45 | 45 | 45 | 45 |
| Reserves | 0 | 1.4k | 1.5k | 1.7k | 1.9k | 2.0k | 2.1k |
| Borrowings | 0 | 338 | 215 | 285 | 413 | 659 | 754 |
| Other Liabilities | 0 | 315 | 470 | 540 | 503 | 561 | 603 |
| Total Liabilities | 0 | 2.0k | 2.2k | 2.6k | 2.9k | 3.3k | 3.5k |
| AssetsFixed Assets | 0 | 782 | 926 | 1.0k | 1.1k | 1.5k | 1.5k |
| CWIP | 0 | 187 | 102 | 137 | 374 | 160 | 305 |
| Investments | 0 | 32 | 87 | 107 | 77 | 187 | 194 |
| Other Assets | 0 | 1.0k | 1.1k | 1.3k | 1.3k | 1.4k | 1.5k |
| Total Assets | 0 | 2.0k | 2.2k | 2.6k | 2.9k | 3.3k | 3.5k |
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 0 | -44 | 250 | 216 | 332 | 262 |
| Cash from Investing | 0 | -139 | -158 | -215 | -414 | -431 |
| Cash from Financing | 0 | 260 | -163 | 10 | 65 | 171 |
| SummaryCapital Expenditure | — | — | — | — | — | — |
| Free Cash Flow | 0 | -185 | 130 | 18 | -112 | -186 |
| FCF Margin | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (25.6×) and current (37.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -3.6% growth and a 26× exit, ₹708 only delivers your return if you pay ₹167. The price is currently baking in 25% growth.
EPS grows -3.6%/yr for 5 years, then fades to 6% over 2, exits at 26×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -3.6% | 18.44 |
| FY28 | -3.6% | 17.78 |
| FY29 | -3.6% | 17.14 |
| FY30 | -3.6% | 16.52 |
| FY31 | -3.6% | 15.93 |
| FY32 | 1.2% ·fade | 16.12 |
| FY33 | 6.0% ·fade | 17.08 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.